Sai Life Sciences Limited researches, develops, and manufactures small-molecule new chemical entities. The company offers tailor-made services to biotech firms and global pharma companies.

In the current Financial Year, the company provided services to over 280 innovator pharmaceutical companies, including more than 230 in that month alone. Among these clients, the company worked with 18 of the top 25 pharmaceutical companies based on their revenue in the calendar year 2023.The services were offered across countries such as the US, the UK, Europe, and Japan. The company’s business development team consists of 16 experienced and qualified professionals, with six located in the US, nine in the UK and Europe, and one in Japan.

For the year/period ended (Rs. in Cr.)

For year/ period ended ( in Cr.)

• One of the largest integrated Indian CRDMOs in terms of revenue from operations for the Financial Year 2024, acting as a one-stop platform for discovery, development and manufacturing.
• CDMO platform with a diverse mix of commercial and under-development molecules
• Fast-growing, integrated Discovery capabilities with focus on biology, chemistry and DMPK services
• Long-standing relationship with a diverse base of existing and new customers
• Modern R&D infrastructure with a differentiated delivery model and strong regulatory track-record
• Experienced management team and Board supported by a qualified scientific talent pool
• Strategic business investments with improving profitability metrics

1. Repayment/prepayment in full or part, of all or certain outstanding borrowings availed by the Company and
2. General corporate purposes

The company is innovation focused CRDMO, NCE, CRO, and CMC entity, and a global player for healthcare related products development. Based on FY25 annualized earnings, the issue appears aggressively priced. Hence, investor may park moderate funds for long term.